Flexible-Dose Trial of Tavapadon in Early Parkinson’s Disease (CVL-751-PD-002)
The Booth Gardner Parkinson’s Care Center is conducting a phase 3, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Who may be eligible to participate?
Men or women, age 40 to 80 years (inclusive) who have been diagnosed with Parkinson’s disease (PD) within 3 years of the screening visit. Other inclusion/exclusion criteria apply.
What does participation involve?
Subjects will be randomized to receive either tavapadon or placebo, once daily. Each subject will participate in the study for up to approximately 35 weeks.
The trial will include:
- Screening Period (maximum of 4 weeks)
- Treatment Period (27 weeks)
- Safety/Withdrawal Assessment Period (10 days)
- Safety Follow-up Period (20 days)
Daniel Burdick, MD, Booth Gardner Parkinson’s Care Center